C1-inhibitor treatment in patients with severe complement-mediated autoimmune hemolytic anemia

Complement-mediated (CM) autoimmune hemolytic anemia (AIHA) is characterized by the destruction of red blood cells (RBCs) by autoantibodies that activate the classical complement pathway. These antibodies also reduce transfusion efficacy via the lysis of donor RBCs. Because C1-inhibitor (C1-INH) is...

Descripción completa

Detalles Bibliográficos
Autores principales: de Boer, Esther C. W., Jalink, Marit, Delvasto-Nuñez, Laura, Meulenbroek, Elisabeth M., Baas, Inge, Janssen, Susanne R., Folman, Claudia C., Gelderman, Kyra A., Wouters, Diana, Engel, Marije D., de Haas, Masja, Kersten, Marie José, Jongerius, Ilse, Zeerleder, Sacha, Vos, Josephine M. I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2023
Materias:
Clinical Trials and Observations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10362545/
https://www.ncbi.nlm.nih.gov/pubmed/36920779
http://dx.doi.org/10.1182/bloodadvances.2022009402

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10362545/
https://www.ncbi.nlm.nih.gov/pubmed/36920779
http://dx.doi.org/10.1182/bloodadvances.2022009402

Ejemplares similares